Form 4: Nurix Therapeutics Executive Gwenn Hansen Reports Stock Transactions

Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Summary

• On April 30, 2025, Gwenn Hansen, the Chief Scientific Officer of Nurix Therapeutics, engaged in transactions involving the company's common stock and restricted stock units (RSUs).
• Hansen acquired 3,206, 2,000 and 3,750 shares of common stock through the vesting of RSUs.
• Simultaneously, Hansen disposed of 3,377 shares of common stock at a weighted average price of $11.5017 to cover tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Hansen directly owns 61,516 shares of Nurix Therapeutics common stock.
• Hansen also holds 9,621, 8,000 and 30,000 restricted stock units.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are routine and related to compensation and tax obligations. There's no indication of unusual activity or concern.

Positives

• The vesting of RSUs indicates that performance milestones have been met, which is a positive sign for the company.

Negatives

• The sale of shares, even if for tax purposes, could be perceived negatively by some investors.

Risks

• Executive stock sales, even for tax obligations, can sometimes create short-term price volatility.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the RSUs implies continued service and potential future vesting events.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and are closely monitored by investors for insights into management's confidence in the company's future prospects. 'Sell to cover' transactions are also common, especially after RSU vesting.

Comparison to Industry Standards

• Executive compensation packages often include RSUs that vest over time, aligning executive interests with long-term shareholder value.
• The vesting schedules described are typical for RSU grants in the biotechnology industry, often spanning three to four years with quarterly vesting.
• The 'sell to cover' practice is a standard method for executives to manage tax obligations associated with RSU vesting, similar to practices at companies like Amgen, Gilead, and Biogen.

Stakeholder Impact

• The transactions have a minor impact on shareholders, potentially causing slight price fluctuations due to the sale of shares.
• Employees may be affected by the company's equity incentive plans and tax withholding policies.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Gwenn Hansen, Chief Scientific Officer, Form 4, Stock Transactions, Restricted Stock Units, RSUs, Beneficial Ownership, Tax Withholding